{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The duration of Response was defined as the time of first recorded achievement of a particular response level, which was defined according to IMWG uniform response criteria, as either complete response, stringent complete response, very good partial response or partial response included only responding participants, until the participants were assessed to have progressive disease.","groups":[{"description":"Bortezomib 1.3 milligram (mg) per meter\\^2 (m\\^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).","id":"OG000","title":"Bortezomib and Dexamethasone"}],"populationDescription":"The study was terminated. Due to insufficient number of participants, the outcome measure data was not analyzed.","reportingStatus":"POSTED","timeFrame":"Day 1 (Start of treatment) until the date of first documented achievement of response","title":"Duration of Response","type":"SECONDARY"}